Molecular dynamics of circadian timing in a mouse model of human sleep disorder

Lead Research Organisation: University of Manchester
Department Name: Life Sciences

Abstract

We have known for some time that daily clocks regulate rhythmical behaviour of sleep and wake in man and other animals. These daily rhythms are endogenous as they free-run in constant conditions, and do not require synchronization to external factors such as light and dark, and are therefore termed circadian ('around a day'). The major rhythm generator of the body resides within the hypothalamus of the brain, and is termed the suprachiasmatic nucleus (or SCN). The SCN has the unique properties that it will continue to oscillate when cultured in laboratory conditions. Genes regulating the circadian clock have been cloned and we know that a key feature regulating timing is how the protein products of these genes cycle in real-time around the cell. This is regulated in part by a class of enzymes called kinases, which add phosphate bonds to the protein (phosphorylation) thereby affecting its activity. One of the best known mutations of the circadian clock is a kinase (CK1e) and was discovered in hamsters over 20 years ago, causing a shortening of circadian period. This was termed the tau mutation, since the term tau is used by circadian biologists to denote period. Mutations in the same or similar kinase systems are known to induce sleep disorders in man. We have re-made this mutation in mice and shown that it accelerates behavioural activity cycles to a similar extent as hamsters. Our proposed work now aims to study how this kinase mutation accelerates the circadian clock, both in the brain and in peripheral body clocks as well. Our earlier research using hamsters has shown that the circadian clock may be accelerated by an abrupt change in phase at a specific time of day, due to accelerated turnover in the nucleus of the cell of core clock proteins. This is equivalent in mechanical terms to a gear box missing a few key cogs, causing it to jump to a new position at each rotation. We aim to test this idea in the mouse by studying protein movements in real-time using new transgenic animals which we aim to create in which key clock proteins are tagged with a fluorescent marker. These types of studies can only be addressed in mice, as these are the only animals in which it is possible to make such genetic modifications. We will use these animals to define how the kinase acts on its target proteins by studying which areas (domains) of the protein are phosphorylated by this kinase. By crossing our clock protein-tagged mice to the tau mutant animals, we will be able to define how tau accelerates period and on which proteins it acts. This is important as a description of how this is achieved could in the longer term lead to the development of novel drugs impacting on sleep and wake cycles in man. Some of core genes involved in the generation of circadian rhythms have been deleted from the genome of mice by genetic modification techniques. These so-called knock-out mice are still rhythmic as other residual clock elements are sufficient to drive behaviour. We will cross our tau mutant mice into these knock out mice and define which of the knock-outs exhibits shortening of wheel-running activity cycles. This will tell us whether tau can act in the absence of a specific gene and also the extent to which it can shorten period. By this means we aim to define which clock gene proteins are likely targets for regulation of behavioural activity cycles by tau. Finally, we aim to capitalize from the fact that the SCN and other tissues continue to oscillate in culture. We will monitor activity of cultured tissues using specialized reporters of clock genes which generate light (luciferase reporters). By monitoring light levels with specialized photon recording equipment, we will be able to examine how the circadian clock regulates timing in tissues, and their responses to stimuli which can re-set the clock.

Technical Summary

Circadian clocks are pervasive regulators of metabolism. Current models of the clock posit auto-regulatory feedback loops in which complexes of their own protein products suppress transcriptional activity of the Per and Cry genes. It is thought that circadian period is determined by complex formation, dissolution and proteosomal degradation, and that phosphorylation controls these rate-limiting processes. Nevertheless, we do not know how circadian proteins turnover in different cellular compartments in real time, how and when they interact, nor how phosphorylation regulates their mobility. This project will capitalize on our creation in mice of the circadian tau mutation, which resides in the catalytic domain of casein kinase (CK)1e, a regulator of clock proteins. The mice exhibit remarkable shortening of behavioural cycles in vivo and acceleration of the clock monitored in vitro by SCN electrical firing rhythms and luciferase imaging of SCN slices and peripheral tissues. We shall characterize how this mutation accelerates period by defining circadian patterns of clock gene mRNA and protein, and studying the re-setting behaviour of the clock, using in vivo and in vitro assays reporting clock gene action with luciferase gene reporters and SCN firing rates. We will define essential clock targets for CK1e by crossing tau mutant animals into mice lacking PER1 or 2 and CRY1 or 2, thereby establishing which components are required for period shortening by tau. We will define the specific phospho-residues within PER targeted by CK1e and raise antibodies for their characterization. We will engineer novel circadian reporter mice using YFP and CFP tagged to PER2 and CRY1. By using single- and dual-wavelength fluorescence and FRET real-time cellular imaging of SCN tissue in culture, we shall determine how these proteins interact over the course of the circadian cycle, and thence define the impact of the tau mutant on their behaviour, both individually and in complex. Joint with BB/E023223/1

Publications

10 25 50
publication icon
Bechtold DA (2010) Circadian dysfunction in disease. in Trends in pharmacological sciences

publication icon
Loudon AS (2007) The biology of the circadian Ck1epsilon tau mutation in mice and Syrian hamsters: a tale of two species. in Cold Spring Harbor symposia on quantitative biology

publication icon
Lu W (2010) A circadian clock is not required in an arctic mammal. in Current biology : CB

publication icon
Meng QJ (2010) Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes. in Proceedings of the National Academy of Sciences of the United States of America

 
Description The role of intracellular transcriptional/post-translational feedback loops (TTFL) within the circadian pacemaker of the suprachiasmatic nucleus (SCN) is well established. In contrast, contributions from G-coupled pathways and cytosolic rhythms to the intercellular control of SCN pacemaking are poorly understood. We therefore combined viral transduction of SCN slices with fluorescence/bioluminescence imaging to visualize GCaMP3-reported circadian oscillations of intracellular calcium [Ca2+]i alongside activation of Ca2+ /cAMP-responsive elements. We phase-mapped them to the TTFL, in time and SCN space, and demonstrated their dependence upon G-coupled vasoactive intestinal peptide (VIP) signaling. Pharmacogenetic manipulation revealed the individual contributions of Gq, Gs, and Gi to cytosolic and TTFL circadian rhythms. Importantly, activation of Gq-dependent (but not Gs or Gi) pathways in a minority of neurons reprogrammed [Ca2+]i and TTFL rhythms across the entire SCN. This reprogramming was mediated by intrinsic VIPergic signaling, thus revealing a Gq/[Ca2+]i-VIP leitmotif and unanticipated plasticity within network encoding of SCN circadian time.
Circadian pacemaking in the suprachiasmatic nucleus (SCN) revolves around a transcriptional/posttranslational feedback loop in which period (Per) and cryptochrome (Cry) genes are negatively regulated by their protein products. Genetically specified differences in this oscillator underlie sleep and metabolic disorders, and dictate diurnal/nocturnal preference. A critical goal, therefore, is to identify mechanisms that generate circadian phenotypic diversity, through both single gene effects and gene interactions. The individual stabilities of PER or CRY proteins determine pacemaker period, and PER/CRY complexes have been proposed to afford mutual stabilization, although how PER and CRY proteins with contrasting stabilities interact is unknown. We therefore examined interactions between two mutations in male mice: Fbxl3(Afh), which lengthens period by stabilizing CRY, and Csnk1e(tm1Asil) (CK1e(Tau)), which destabilizes PER, thereby accelerating the clock. By intercrossing these mutants, we show that the stabilities of CRY and PER are independently regulated, contrary to the expectation of mutual stabilization. Segregation of wild-type and mutant alleles generated a spectrum of periods for rest-activity behavior and SCN bioluminescence rhythms. The mutations exerted independent, additive effects on circadian period, biased toward shorter periods determined by CK1e(Tau). Notably, Fbxl3(Afh) extended the duration of the nadir of the PER2-driven bioluminescence rhythm but CK1e(Tau) reversed this, indicating that despite maintained CRY expression, CK1e(Tau) truncated the interval of negative feedback. These results argue for independent, additive biochemical actions of PER and CRY in circadian control, and complement genome-wide epistatic analyses, seeking to decipher the multigenic control of circadian pacemakingCircadian pacemaking requires the orderly synthesis, posttranslational modification, and degradation of clock proteins. In mammals, mutations in casein kinase 1 (CK1) epsilon or delta can alter the circadian period, but the particular functions of the WT isoforms within the pacemaker remain unclear. We selectively targeted WT CK1epsilon and CK1delta using pharmacological inhibitors (PF-4800567 and PF-670462, respectively) alongside genetic knockout and knockdown to reveal that CK1 activity is essential to molecular pacemaking. Moreover, CK1delta is the principal regulator of the clock period: pharmacological inhibition of CK1delta, but not CK1epsilon, significantly lengthened circadian rhythms in locomotor activity in vivo and molecular oscillations in the suprachiasmatic nucleus (SCN) and peripheral tissue slices in vitro. Period lengthening mediated by CK1delta inhibition was accompanied by nuclear retention of PER2 protein both in vitro and in vivo. Furthermore, phase mapping of the molecular clockwork in vitro showed that PF-670462 treatment lengthened the period in a phase-specific manner, selectively extending the duration of PER2-mediated transcriptional feedback. These findings suggested that CK1delta inhibition might be effective in increasing the amplitude and synchronization of disrupted circadian oscillators. This was tested using arrhythmic SCN slices derived from Vipr2(-/-) mice, in which PF-670462 treatment transiently restored robust circadian rhythms of PER2::Luc bioluminescence. Moreover, in mice rendered behaviorally arrhythmic by the Vipr2(-/-) mutation or by constant light, daily treatment with PF-670462 elicited robust 24-h activity cycles that persisted throughout treatment. Accordingly, selective pharmacological targeting of the endogenous circadian regulator CK1delta offers an avenue for therapeutic modulation of perturbed circadian behavior.
Exploitation Route These studies have yielded significant publication outputs and in addition point towards the use of selective CK1 inhibitors for use in man in re-setting disrupted circadian function. This is currently the subject of intense research interest by pharma - Pfizer - and recently this company has invested further resources in our group in the form of CASE student support.
Sectors Healthcare,Pharmaceuticals and Medical Biotechnology

 
Description GSK Collaboration 
Organisation GlaxoSmithKline (GSK)
Department GlaxoSmithKline Medicines Research Centre
Country United Kingdom 
Sector Private 
PI Contribution We have signed a formal collaborative agreement between the University of Manchester and GSK (2009-2014) to develop new chronotherapeutic drugs
Collaborator Contribution Provision of reagents and design of new tool compounds, support for in-vivo research, support for CASE students (3), IPA and MICA awards (BBSRC/MRC).
Impact Extensive publications including Nature Medicine, PNAS, Nucleic Acid Research, J. Cell Sci.
 
Description Day of Body Clock 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact There was a special BBC "Day of the Body Clock" event which our team at Manchester played a central role in co-ordinating and involved multiple media interviews (Radio, TV and Press).
Year(s) Of Engagement Activity 2014
URL https://lsmanchesterblog.wordpress.com/2014/05/12/body-clock-day-on-the-bbc/